Insulin Glargine During and After the Period of Fasting in Ramadan
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
Primary Objectives :
- To compare the number of hypoglycaemic events (severe, symptomatic, asymptomatic,
nocturnal) in patients with type 2 diabetes treated with insulin glargine (Lantus®) and
glimepiride (Amaryl®), before, during and after the period of fasting in Ramadan.
Secondary Objectives :
- To assess glycaemic control before, during and after Ramadan in terms of HbA1c, FBG, and
8-point blood glucose profile (FBG and 8-point blood glucose profile will be collected
with a blood glucose monitor through a monthly patient diary).
- To assess the relationship between hypoglycaemia events during Ramadan and blood glucose
control prior and during Ramadan.
- To assess patient satisfaction
- To document adverse events (all serious adverse events, non serious adverse events)
throughout the study (all events will be collected through the monthly patient diary).